Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published on July 27
The EU approval of Kisunla marks a pivotal shift in Alzheimer's treatment, creating new demand for genetic testing and imaging services that these companies provide.
These aren't optional services but required components for safe drug administration. Every patient needs genetic testing and ongoing monitoring, creating sustained revenue streams.
As the first approved drug in this new class, Kisunla sets the standard for future treatments, positioning these support companies at the forefront of an emerging market.
The EU approval of Eli Lilly's Alzheimer's drug Kisunla creates a new investment ecosystem. This breakthrough validates treatments that slow cognitive decline and opens opportunities in the essential support services required for safe drug administration and patient monitoring.
This group focuses on companies providing critical services like genetic testing to identify suitable patients and advanced medical imaging to monitor for side effects. These services are mandatory requirements, not optional add-ons, creating sustained demand potential.
These companies were handpicked by professional analysts as the key players in the Alzheimer's treatment support network. They represent the specialized firms positioned to benefit from increased demand as this new class of therapies enters the market.
Concise interpretation of basket market capitalisation and investor takeaways.
LLY: $756.76B
BIIB: $21.44B
ILMN: $15.21B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+131.36%
On average, analysts expect assets in this group to grow 131.36% over the next year.
11 of 15 assets in this group are rated Buy by professional analysts.
